Donanemab – what we know about the latest Alzheimer’s drug
Donanemab can slow the progression of Alzheimer’s disease.But what is the drug and how does it work? Here your questions on the latest development in Alzheimer’s research are answered.– What kind of treatment is Donanemab?
Donanemab: What is the new Alzheimer’s drug rejected for use on the NHS
Donanemab: Everything we know about the latest Alzheimer’s drug rejected by the NHS - Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in researc
U.K.’s cost-effectiveness agency says Alzheimer’s drug donanemab does not provide good value
For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its costs.
NICE rejects Alzheimer’s drug donanemab owing to cost and “significant health risks”
The National Institute for Health and Care Excellence (NICE) has rejected the Alzheimer’s drug donanemab because the “relatively small benefit” it provides does not outweigh its cost.1 The draft guidelines,
New Alzheimer’s drug approved in UK, but government won’t pay for it
The drug is the second Alzheimer’s medicine to receive a lukewarm reception from the UK government in recent months.View on euronews
UK approves Lilly's Alzheimer's drug, but deemed 'too expensive' for wide use
UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Eli Lilly's treatment for early Alzheimer's, the company said on Wednesday.
UK regulator approves second Alzheimer's drug in months but government won't pay for it
Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after an independent watchdog agency said the treatment isn’t worth the cost to t
Eli Lilly Alzheimer’s drug rejected as too expensive by UK’s NHS, FT reports
The UK’s healthcare spending watchdog has rejected Eli Lilly’s (LLY) Alzheimer’s drug as being too expensive despite being
England’s Drug-Cost Watchdog Rejects Eli Lilly’s Alzheimer’s Drug
Regulator cited significant uncertainties about the drug’s benefits, as well as the high costs to treat its severe side effects.
Live news: Second Alzheimer’s drug deemed too expensive for UK’s NHS
Keep abreast of significant corporate, financial and political developments around the world. Stay informed and spot emerging risks and opportunities with independent global reporting, expert commentary and analysis you can trust.
NHS will not fund new drug to slow Alzheimer’s
A new drug that slows the pace of Alzheimer's disease is too expensive for too little benefit to be used on the NHS, the watchdog says.
News Medical on MSN6h
MHRA greenlights donanemab for early stage Alzheimer’s disease
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 October 2024, approved a license for the ...
Outsourcing-pharma3d
NICE rejects Donanemab for NHS use despite MHRA approval
Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...
Tens of thousands to be recruited into Alzheimer’s trials after landmark drug rejected
Tens of thousands of people will be recruited into Alzheimer’s trials after a landmark drug was rejected for use on the NHS.
Alzheimer's Society3d
Alzheimer's Society responds to MHRA and NICE announcements on donanemab
The MHRA have approved donanemab for the treatment of Alzheimer’s disease. However, NICE does not recommend use on the NHS ...
National Institute for Health and Care Excellence3d
New Alzheimer’s treatment donanemab does not currently demonstrate value for the NHS says NICE
Donanemab (also called Kisunla and made by Eli Lilly) has been licensed today by the MHRA for treatment of mild cognitive impairment or mild dementia due to Alzheimer’s disease in some adults. It is a ...
Second ‘game-changing’ Alzheimer’s drug donanemab gets green light in UK – but WON’T be available on NHS
A SECOND “game-changing” Alzheimer’s drug shown to slow the progression of the disease has been approved in the UK. Donanemab, developed by pharmaceutical giant Eli Lilly, was ...
Arkansas group suggests ways to improve care for Alzheimer’s, dementia patients
Expanding public education, increasing access and quality of care, supporting family caregivers and increasing training for ...
Surrey Alzheimer's drug trial patient shares his experience of donanemab
Diagnosed with mild cognitive impairment (MCI) in 2018, Mr Almond, from Esher, took part in two 18-month trials for donanemab ...